NRAS mutation in differentiated thyroid cancer

[1]  C. Berking,et al.  Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  V. Marotta,et al.  Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer , 2021, Cancers.

[3]  S. Nissar,et al.  RAS mutations and colorectal cancer: Testing and precision medicine , 2021 .

[4]  K. Chatterjee,et al.  Extended RAS mutations (KRAS and NRAS) in patients with colorectal cancers in eastern India: An observational study , 2021 .

[5]  J. Klubo-Gwiezdzinska,et al.  Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review , 2020, Cancers.

[6]  C. Garbe,et al.  Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover , 2020, Cancers.

[7]  B. Solomon,et al.  Mitogen-activated protein kinase pathway inhibition for re-differentiation of radioiodine-refractory differentiated thyroid cancer: an evolving protocol. , 2019, Thyroid : official journal of the American Thyroid Association.

[8]  M. Hidalgo,et al.  A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours , 2018, British Journal of Cancer.

[9]  D. Schadendorf,et al.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[10]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[11]  AACR Project GENIE: Powering Precision Medicine through an International Consortium. , 2017, Cancer discovery.

[12]  M. Nikiforova,et al.  Tumor genotype determines phenotype and disease-related outcomes in thyroid cancer: a study of 1510 patients. , 2015, Annals of surgery.

[13]  Steven J. M. Jones,et al.  Genomic Classification of Cutaneous Melanoma , 2015, Cell.

[14]  J. Desai,et al.  A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors. , 2014 .

[15]  V. D. Di Crescenzo,et al.  Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review , 2013, BMC Surgery.

[16]  K. Flaherty,et al.  Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.

[17]  V. Sondak,et al.  Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (S0438) , 2012, Clinical Cancer Research.

[18]  J. Settleman,et al.  Isoform-specific ras functions in development and cancer. , 2009, Future oncology.

[19]  L. Chow,et al.  A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors , 2008, Cancer Chemotherapy and Pharmacology.

[20]  E. Kaplan,et al.  N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. , 1994, Surgery.

[21]  N. Lemoine,et al.  High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. , 1989, Oncogene.

[22]  L. Old,et al.  Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity? , 1984, Nature.

[23]  C. Marshall,et al.  A transforming gene present in human sarcoma cell lines , 1982, Nature.